DSKYF Message Board Post 9273102 | Daiichi Sankyo Co Ltd
home / stock / dskyf / dskyf message board
kenta23
(investorshub)
Posted on: Jun/03/2018 20:44:59
Source: investorshub
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141265811
Dead boards are FUN!!!!!!!!!!!!!!!!!!!!
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
Market:
-
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
-
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
-
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...